Allergy Therapeutics plc, which trades on AIM under the code AGY, describes itself as a fully integrated commercial biotechnology company specialising in allergy immunotherapies. It sells treatments designed to modify the immune response to allergens such as pollen, and it develops next-generation products, including …
Egetis Therapeutics (LSE:0ABW), the Stockholm-headquartered rare disease company with operations in the US and Europe, announced on 28 September 2026 that the FDA has approved EMCITATE (tiratricol). The approved indication is the treatment of peripheral thyrotoxicosis in adult and paediatric patients with monocarboxylate transporter …
On 3 September 2026, Futura announced a placing, subscription and retail offer at 0.2 pence per share, alongside the launch of a formal sale process and M&A process under theTakeoverCode, which began an offer period. The company said the current market valuation does not …
Convatec Group Plc — LSE:CTEC closed 0.86% higher on28 September 2026, with the shares at 211.20p after a gain of 1.80p on the day.
Smith & Nephew Plc — LSE:SN closed 0.89% higher on28 September 2026, with the shares at 1,017.00p after a gain of 9.00p on the day.
NIOX Group describes itself as a medical device company specialising in point-of-care FeNO testing, used in the diagnosis and management of asthma and COPD. FeNO, or fractional exhaled nitric oxide, is measured from a patient's breath, and the group's NIOX devices are designed for …
Oxford Nanopore Technologies PLC shares rose 2.48% today to 186.10p, up 4.50p, according to the market data provided.
The move appears to be apartial reboundafter the shares fell around 5% following the company's full-year results on 24 September. There does not appear to be a new company-specific announcement today, and the gain comes alongside a firmer session for UK mid-caps.
ImmuPharma has recorded a15.44% gain on 28 September 2026, bringing renewed attention to LSE:IMM.
MicroSalt (LSE:SALT) has attracted renewed market attention after climbing14.29% on 28 September 2026. The move comes immediately ahead of a potentially important period for the company, with interim financial results due on 29 September and the current retail fundraising process approaching its deadline.